Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06784336 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation
A Phase 2 study of Allogeneic Stem Cell Transplant, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06784336 is a Phase 2 study of Allogeneic Stem Cell Transplant that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06784336, a Phase 2 study of Allogeneic Stem Cell Transplant, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will evaluate the safety and early efficacy of administering the combination of a commercially available potato-based resistant starch along with iron chelation therapy to subjects undergoing alloHCT.
Conditions Studied
Interventions
- DRUG Iron chelation
- DRUG Potato Resistant Starch
Study Locations (1)
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-10-15 |
| Est. Completion | 2029-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06784336
The ClinicalTrials.gov registry entry for NCT06784336 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allogeneic Stem Cell Transplant appearing as the primary indexed condition, and to 2 interventions - of which Iron chelation is the first listed.
NCT06784336 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT06784336 about?
NCT06784336 is a clinical study titled "Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation". The study will evaluate the safety and early efficacy of administering the combination of a commercially available potato-based resistant starch along with iron chelation therapy to subjects undergoing alloHCT.
What is the current status of trial NCT06784336?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-10-15. Estimated completion is 2029-10.
What conditions does trial NCT06784336 study?
This clinical trial studies the following conditions: Allogeneic Stem Cell Transplant.
What interventions are being tested in trial NCT06784336?
The interventions under investigation include: Iron chelation (DRUG), Potato Resistant Starch (DRUG).
Who is sponsoring clinical trial NCT06784336?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06784336 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allogeneic Stem Cell Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.